AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 DEC 12 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., (BTPH) has licensed its Bio-Vant vaccine adjuvant on a nonexclusive basis to Corixa Corp. (CRXA) for use in several potential vaccines to be developed by Corixa. This agreement is a result of Corixa's completion of feasibility studies using Bio-Vant with certain Corixa protein antigens and DNA.
"We are extremely pleased by this license agreement with Corixa, one of the premier biotechnology vaccine developers in the world," said Stephen M. Simes, BioSante's president and chief executive officer. "This helps validate our preclinical and clinical work with Bio-Vant and gives credence to the value of our partner-funded feasibility studies. Several other unannounced partner-funded feasibility studies also are under way with both biotech and pharmaceutical companies."
Under the agreement, Corixa has agreed to pay BioSante milestone payments upon the achievement by Corixa of certain milestones plus royalty payments on sales by Corixa if and when vaccines are approved using Bio-Vant and commercialized. If Corixa sublicenses vaccines that include Bio-Vant, BioSante will share in milestone payments and royalties received by Corixa. The license agreement covers access to Bio-Vant for a variety of cancer, infectious and ...
Source: HighBeam Research, BioSante Licenses Technology To Corixa.(Brief Article)